{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.9","upperLimit":"23.8","value":"20.0"},{"groupId":"OG001","lowerLimit":"12.9","upperLimit":"15.5","value":"14.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"354"}],"units":"Participants"}],"title":"HER2-low Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.9","upperLimit":"23.8","value":"20.3"},{"groupId":"OG001","lowerLimit":"13.5","upperLimit":"15.9","value":"14.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"title":"ITT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"436"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"PFS2 was defined as time from randomization to second progression (the earliest of the progression event subsequent to first subsequent therapy) or death; second progression was defined according to local standard clinical practice and might involve any of the following: objective radiological imaging, symptomatic progression, or death. Median PFS2 was calculated using Kaplan-Meier method and its CI using Brookmeyer-Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received T-DXd 5.4 mg/kg via IV infusion every 3 weeks until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG000","title":"T-DXd"},{"description":"Participants received Investigator's choice single-agent chemotherapy (capecitabine 1000 or 1250 mg/m\\^2 orally twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles, paclitaxel 80 mg/m\\^2 via IV infusion qw in 3-week cycles or nab-paclitaxel 100 mg/m\\^2 via IV infusion qw for 3 weeks followed by 1-week rest period in 4-week cycles) until PD, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation was met.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The HER2-low population included subset of participants in ITT population with HER2 IHC 2+/ISH- and IHC 1+ as determined per IRT data for HER2 IHC expression. The ITT population included all randomized participants. Only participants with data collected in specified categories are reported.","reportingStatus":"POSTED","timeFrame":"Response evaluations performed at screening, q6w ± 1 week from randomization for 48 weeks, and then q9w ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)","title":"Time From Randomization to Second Progression or Death (PFS2) in the Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-low and Intent-to-Treat Population","type":"SECONDARY","unitOfMeasure":"months"}